During the lead optimisation stage of the drug discovery pipeline, we might wish to make mutations to an initially identified binding antibody to improve properties such as developability, immunogenicity, and affinity.

There are many ways we could go about suggesting these mutations including using Large Language Models e.g. ESM and AbLang, or Inverse Folding methods e.g. ProteinMPNN and AntiFold. However, some of our recent work (soon to be pre-printed) has shown that classical non-Machine Learning approaches, such as BLOSUM, could also be worth considering at this stage.